Core Viewpoint - The article highlights the efforts of Dong'e Ejiao Co., Ltd. in preserving traditional Chinese medicine practices while embracing innovation and technology to meet modern consumer demands [1][4]. Group 1: Traditional Craftsmanship and Innovation - Dong'e Ejiao's production techniques are recognized as a national-level intangible cultural heritage, reflecting nearly 3,000 years of history [3]. - The company integrates modern technology with traditional methods, such as the use of steam ball skin machines to enhance production efficiency [3]. - The introduction of a fully automated production line for traditional Chinese medicine oral liquids represents a significant advancement in standardizing production processes [3]. Group 2: Consumer Engagement and Technology - Dong'e Ejiao collaborates with Anhui University of Chinese Medicine to implement AI tongue diagnosis technology, allowing consumers to receive personalized health plans based on uploaded tongue images [4]. - As of June this year, the company has recorded over 520,000 online appointments for traditional gel preparation and more than 12,000 intelligent body assessments [4]. Group 3: Cultural Tourism and Experience - The old factory site has been transformed into a cultural experience hotel, contributing to the Dong'e Traditional Chinese Medicine Cultural Tourism Zone, which includes various attractions [5]. - The tourism area is expected to receive over 1.3 million visitors in 2024, providing immersive experiences that promote the cultural significance of Ejiao [5]. - Dong'e Ejiao emphasizes the synergy between promoting traditional Chinese medicine culture and business development, viewing it as both a responsibility and a mission [5].

Core Points - The new regulation mandates that from July 1, 2023, medical institutions must scan drug traceability codes before settling with medical insurance funds, enhancing drug safety [1] - By January 1, 2026, all medical institutions are required to fully collect and upload drug traceability codes, establishing a comprehensive tracking system for pharmaceuticals [1] - The traceability code acts as a unique electronic identity for each drug, ensuring that each box of medication has a single sales record, thus preventing counterfeit and swapped drugs [1] Industry Impact - The integration of drug traceability codes with medical insurance is significant for public drug safety, effectively combating issues like "returned drugs" and fraudulent transactions [2] - The traceability system allows for precise monitoring of high-priced drugs, ensuring they are used appropriately and reach the patients in need [2] - The National Medical Insurance Administration has already demonstrated the effectiveness of this system by investigating the traceability codes of specific drugs, thereby safeguarding both drug safety and insurance funds [2] Public Engagement - Consumers are encouraged to actively participate in ensuring their own drug safety by following six key practices when purchasing medications, including verifying the presence of traceability codes and scanning them for authenticity [3] - The promotion of drug traceability codes is essential, with the goal of making the scanning process a standard practice in every drug transaction [3] - Strengthening regulatory measures around drug traceability codes will help close potential loopholes and enhance public health protection [3]

"孩子们，这就是蒸球化皮机，它的发明大大提升了熬胶效率……"夏日，东阿阿胶（000423）产业园区 的阿胶探秘长廊里，一群小学生正在讲解员引领下开展研学之旅，小眼睛里充满了好奇。 "叔叔阿姨，您知道阿胶的传统制作技艺有多少道工序吗？"另一边，一群银发长者正沿着参观步道进入 阿胶世界体验工厂，隔着玻璃可以看到阿胶、阿胶糕、复方阿胶浆等产品的生产过程。长廊中弥漫着浓 浓的胶香、枣香与中草药香味。 阿胶，中药瑰宝，滋补养生——不少消费者有这样的总体印象。但阿胶从何而来？一味中药如何拉动多 元产业？古老药材如何走进年轻消费者中间？日前，记者跟随国务院国资委新闻中心"走进新国企"采访 活动，走进东阿阿胶股份有限公司，感受老字号向新跃动的活力。 阿胶怎么吃？在较为费时耗力的熬胶之外，还能有创新解法吗？近年来，东阿阿胶推出"小金条"东阿阿 胶速溶粉，可以冲泡饮品、拌酸奶，满足年轻消费者随时随地"撒个胶"的需求。此外，与奈雪的茶联名 推出阿胶奶茶；推出即食饮品"锦上花"滋补生活茶；与迪士尼推出白雪公主联名套装……这让消费者看 到了阿胶的多种样态，也让人感叹"阿胶做出了国潮范儿"。 "产品即食化是通过技术创新来满足消费需求，实 ...

Core Insights - The company is transforming its traditional manufacturing processes through smart manufacturing and AI technology, enhancing efficiency and product quality [1][2] - Financial performance shows significant growth, with revenue increasing from 3.849 billion to 5.921 billion and net profit rising from 440 million to 1.557 billion from 2021 to 2024 [1] - The company is focusing on digital transformation of its supply chain, which has led to an increase in gross margin from 47.57% in 2019 to 72.42% in 2024 [2] Digital Transformation and Product Development - The company is implementing AI-driven quality control and IoT-based environmental monitoring to enhance manufacturing capabilities [2] - New product lines such as "Peach Blossom Princess" and "Dong'e Ejiao Little Gold Bar" are expanding market reach and catering to consumer preferences [2] - The company is targeting the male health market, developing products like Ejiao and Cistanche raw liquid to create a comprehensive product matrix [2][3] Future Strategy and R&D Focus - The company plans to integrate primary, secondary, and tertiary industries to enhance resource supply, product innovation, and cultural tourism [3] - Five key R&D areas have been identified: innovation in gelatin-based medicines, major variety cultivation, new drug development, health consumer product development, and leading the donkey industry [3] - Increased investment in R&D and the establishment of a high-standard innovation system are priorities to enhance core competitiveness [3]

Core Insights - Dong'e Ejiao is leveraging digital transformation and automation to enhance production efficiency and quality control [1][2][3] Group 1: Production Innovations - Dong'e Ejiao has replaced manual glass bottle inspections with automated light inspection machines, improving accuracy and reducing worker fatigue [1] - The company has developed a six-axis robot for bottle handling, reducing the number of operators needed from five to two, thus lowering labor intensity [1] Group 2: Digital Management Systems - A digital signage production warning system has been implemented to achieve digital and visual management of the production process [2] - The optimization of the production and sales collaboration platform in 2024 has led to a 30% increase in planning accuracy, with main product planning accuracy exceeding 90% [2] Group 3: Supply Chain and Resource Management - Dong'e Ejiao has established a smart supply chain system that utilizes AI to predict and manage raw material supply, ensuring timely delivery [3] - The company has integrated technology and industry innovation to create a comprehensive digital system covering research, production, supply, sales, and inventory [3]

股票代码：000423 股票简称：东阿阿胶 五、关于管理层的稳定性与战略执行 未来一定时期内，管理团队将保持总体稳定，上下同欲，坚定执行 "1238"战略，推动公司经营稳健发展。 东阿阿胶股份有限公司 2024 年年度股东大会记录表 编号：2025-04 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 □业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | √现场参观□其他 | | 参与单位名称 | 参加公司 2024 年年度股东大会的股东及委托代理人 | | 及人员姓名 | | | 时间 | 2025 年 5 月 20 日 | | 地点 | 山东省东阿县阿胶街 78 号 公司会议室 | | | 董事长程杰 | | 上市公司 | 独立董事 文光伟 | | 接待人员姓名 | 董事、副总裁、董事会秘书、财务总监丁红岩 | | | 证券事务代表、董事会办公室总经理 付延 一、关于股份回购的规划 | | | 作为市值管理工具之一，股份回购在提振资本市场信心、稳定股价 等方面具有一定作用。基于当前经营实际，公司将保持对股份回购等事 | | | 项的 ...

Group 1 - Kanghong Pharmaceutical's Shugan Jieyu capsules achieved double-digit growth year-on-year, surpassing the overall growth of the antidepressant market [1] - The capsules have advantages such as faster efficacy, fewer side effects, and high long-term safety, which alleviate patients' psychological burden [1] - Clinical research for anxiety disorders is progressing steadily, with Phase III clinical trial enrollment expected to be completed by April 2025, potentially expanding the target population [1] Group 2 - Dong'e Ejiao emphasized the importance of sustainable supply of donkey hide, with current prices remaining stable [2] - In 2024, the revenue share of Ejiao blocks is approximately 45%, while the revenue share of compound Ejiao paste is nearly 35% [2] - The price of donkey hide is influenced by various factors, including breeding costs, scale, and import conditions [2] Group 3 - Hengrui Medicine launched a global public offering of 224.52 million H-shares, with a price range set between HKD 41.45 and HKD 44.05 per share [3] - The offering includes a 5.5% allocation for public sale in Hong Kong and 94.5% for international placement [3] - Seven cornerstone investors have subscribed for over HKD 4.1 billion (approximately USD 533 million), accounting for 43.04% of the offering size [3] Group 4 - Pianzaihuang reported that the current domestic market price for cow bile is between RMB 1.65 million and RMB 1.8 million per kilogram [4] - The company is actively engaging with policies regarding the import of cow bile, currently only allowing imports from Argentina [4] - The new import policy has minimal short-term impact on domestic cow bile prices, with no detailed guidance from government authorities yet [4] Group 5 - Changchun High-tech is in Phase III clinical trials for adult growth hormone deficiency indications [5] - The company maintains a rational attitude towards the sales growth of growth hormone products, focusing on stability and market expansion [5] - Research on the combination of semaglutide for muscle gain and fat loss is in the Investigator Initiated Trial phase [5] Group 6 - Kangzhi Pharmaceutical is preparing for the resumption of production for its Re Yan Ning granules, expected to be launched in the market by July-August this year [6] - The company is committed to the development of traditional Chinese medicine, enhancing existing products through secondary development [6] Group 7 - ST Huluwawa is leveraging the advantages of the Hainan Free Trade Port policy to establish a cross-border e-commerce platform [7] - The company aims to enhance operational efficiency and focus on the children's health consumption market [7] - A comprehensive O2O and online channel platform is being constructed to support product market coverage [7]

股票代码：000423 股票简称：东阿阿胶 东阿阿胶股份有限公司投资者关系活动记录表 编号：2025-03 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 □业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 √其他 | | 参与单位名称 参加 及人员姓名 | 2025 年山东辖区上市公司投资者网上集体接待日活动的投资者 | | 时间 | 2025 年 5 月 15 日（周四）15:00—16:30 | | 地点 | 全景网"投资者关系互动平台"（http://rs.p5w.net） | | | 董事长 程杰 | | 上市公司 | 董事、总裁 孙金妮 | | 接待人员姓名 | 董事、副总裁、董事会秘书、财务总监 丁红岩 | | | 证券事务代表、董事会办公室总经理 付延 一、关于公司未来经营规划 | | | 东阿阿胶将坚定以"1238"战略为指引，深化推进胶类产业链 "三产融合"协同发展，继续做强做优做大阿胶主业，精准拓深基石业 | | | 务，统筹拓展潜力产品，着力培育外延品种。持续深化"一中心 三高 | | 地+N | ...

Core Insights - The company is focusing on its product segmentation, with approximately 45% of revenue coming from traditional Ejiao blocks and nearly 35% from compound Ejiao syrup in 2024 [1] - The brand Royal Weichang 1619 aims to strengthen its position in the men's health sector, emphasizing a vision of upgrading the Northeast industry and focusing on key strategies for brand and product development in 2025 [1] - The company is committed to ensuring a stable supply of donkey hides, which are crucial for its production, while maintaining a balance between domestic and international sourcing [1] Financial Performance - In the first quarter, the company reported good terminal sales performance and reassessed its strategic credit support based on the scale of cooperation with strategic clients [2] - The accounts receivable increased compared to the beginning of the year, but the management indicated that the sales collection and accounts receivable levels remain reasonable and controllable [2] - The company plans to maintain its established credit management strategy to ensure a healthy level of accounts receivable [2] Strategic Initiatives - The company is enhancing its brand strategy for the "Peach Blossom Princess" line, focusing on revitalizing the brand and establishing its position in the beauty and health market [1] - The management is increasing the procurement of strategic materials such as donkey hides and traditional Chinese medicinal herbs, which has led to higher capital expenditures [2] - The company expects to see an increase in cash flow from operations as bank acceptance bills mature and collections improve [2]

Core Insights - The company achieved a revenue of 5.921 billion yuan in 2024, representing a year-on-year growth of 25.57% and a net profit attributable to shareholders of 1.557 billion yuan, up 35.29% [1] - The company is driven by a dual engine of pharmaceutical and health consumer products, with significant growth in its core product lines [2] - The company has introduced an employee stock incentive plan to enhance talent attraction and promote long-term high-quality development [2] Financial Performance - In 2024, the company reported a net operating cash flow of 2.171 billion yuan, reflecting an 11.13% increase year-on-year [1] - The basic earnings per share (EPS) for 2024 was 2.42 yuan, marking a 35.20% increase compared to the previous year [1] - The company maintained a strong financial structure with a debt-to-asset ratio of 21.05% and cash reserves of 5.015 billion yuan at the end of the year [2] Business Segments - Revenue from the company's Ejiao and related products reached 5.544 billion yuan, a year-on-year increase of 27.04%, with a gross margin of 73.61% [2] - Other pharmaceuticals and health products generated revenue of 236 million yuan, up 26.19% year-on-year [2] - The company experienced a decline in revenue from donkey breeding and sales, which amounted to 69 million yuan, down 28.92% [2] Growth Initiatives - The company launched a stock incentive plan, proposing to grant up to 124.72 million restricted shares, representing 0.19% of the total share capital, to 179 key personnel [2] - The performance targets for the incentive plan include a compound annual growth rate of net profit attributable to shareholders of no less than 15% from 2025 to 2027 [2] - The company has a history of high dividends, with a mid-year dividend of 737 million yuan in 2024, representing 99.77% of the net profit attributable to shareholders for the first half of the year [2] Investment Outlook - The company is expected to achieve EPS of 2.87 yuan, 3.40 yuan, and 4.02 yuan for the years 2025 to 2027, with corresponding dynamic P/E ratios of 21.91, 18.53, and 15.66 [3] - As a leader in the Ejiao industry, the company possesses strong brand barriers and is anticipated to achieve steady growth in performance [3]